Søren Hardt-Lindberg

Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics

G. Hovingh, A. Lincoff, S. Kahn, 2022, Obesity.

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.

I. Lingvay, K. Brown-Frandsen, Steven E. Kahn, 2023, The New England journal of medicine.

Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial

John E. Poremba, H. Randeva, P. Borne, 2024, The Lancet.